Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
|
3 Months Ended |
Jun. 30, 2016 |
Jun. 30, 2015 |
| Cash Flows From Operating Activities: |
|
|
| Net loss |
$ (494,183)
|
$ (402,826)
|
| Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
| Depreciation and Amortization |
4,917
|
4,077
|
| Changes in assets and liabilities: |
|
|
| Prepaid expenses and other receivables |
34,573
|
9,085
|
| Accounts payable and other liabilities |
41,876
|
35,064
|
| Prepayment to related party for clinical trials |
0
|
177,794
|
| Net cash used in operating activities |
(412,817)
|
(176,806)
|
| Cash Flows from Investing Activities: |
|
|
| Purchase of property and equipment |
0
|
(4,767)
|
| Purchase of intangible assets |
(34,769)
|
(48,611)
|
| Net Cash used in investing activities |
(34,769)
|
(53,378)
|
| Cash Flows From Financing Activities: |
|
|
| Advances from related party |
193,419
|
0
|
| Net cash provided by financing activities |
193,419
|
0
|
| Net increase (decrease) in cash |
(254,167)
|
(230,184)
|
| Effect of exchange rate changes on cash |
(655,649)
|
1,266
|
| Cash at beginning of period |
9,403,965
|
354,749
|
| Cash at end of period |
$ 8,494,149
|
$ 125,831
|